Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia

Vladimir Vainstein, Christopher A. Eide, Thomas O'Hare, Ofir Shukron, Brian Druker

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

BCR-ABL mutations result in clinical resistance to ABL tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Although in vitro 50% inhibitory concentration (IC50) values for specific mutations have been suggested to guide TKI choice in the clinic, the quantitative relationship between IC50and clinical response has never been demonstrated. We used Hill's equation for in vitro response of Ba/F3 cells transduced with various BCR-ABL mutants to determine IC50 and the slope of the dose-response curve. We found that slope variability between mutants tracked with in vitro TKI resistance, provides particular additional interpretive value in cases where in vitro IC50and clinical response are disparate. Moreover, unlike IC50alone, higher inhibitory potential at peak concentration (IPP), which integrates IC50, slope, and peak concentration (Cmax), correlated with improved complete cytogenetic response (CCyR) rates in CML patients treated with dasatinib. Our findings suggest a metric integrating in vitro and clinical data may provide an improved tool for BCR-ABL mutation-guided TKI selection.

Original languageEnglish (US)
Pages (from-to)3331-3334
Number of pages4
JournalBlood
Volume122
Issue number19
DOIs
StatePublished - Nov 7 2013

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Phosphotransferases
Inhibitory Concentration 50
Mutation
Cytogenetics
In Vitro Techniques

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia. / Vainstein, Vladimir; Eide, Christopher A.; O'Hare, Thomas; Shukron, Ofir; Druker, Brian.

In: Blood, Vol. 122, No. 19, 07.11.2013, p. 3331-3334.

Research output: Contribution to journalArticle

Vainstein, Vladimir ; Eide, Christopher A. ; O'Hare, Thomas ; Shukron, Ofir ; Druker, Brian. / Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia. In: Blood. 2013 ; Vol. 122, No. 19. pp. 3331-3334.
@article{b989fe7423ec4e7a8f93544005943d1a,
title = "Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia",
abstract = "BCR-ABL mutations result in clinical resistance to ABL tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Although in vitro 50{\%} inhibitory concentration (IC50) values for specific mutations have been suggested to guide TKI choice in the clinic, the quantitative relationship between IC50and clinical response has never been demonstrated. We used Hill's equation for in vitro response of Ba/F3 cells transduced with various BCR-ABL mutants to determine IC50 and the slope of the dose-response curve. We found that slope variability between mutants tracked with in vitro TKI resistance, provides particular additional interpretive value in cases where in vitro IC50and clinical response are disparate. Moreover, unlike IC50alone, higher inhibitory potential at peak concentration (IPP), which integrates IC50, slope, and peak concentration (Cmax), correlated with improved complete cytogenetic response (CCyR) rates in CML patients treated with dasatinib. Our findings suggest a metric integrating in vitro and clinical data may provide an improved tool for BCR-ABL mutation-guided TKI selection.",
author = "Vladimir Vainstein and Eide, {Christopher A.} and Thomas O'Hare and Ofir Shukron and Brian Druker",
year = "2013",
month = "11",
day = "7",
doi = "10.1182/blood-2012-08-452409",
language = "English (US)",
volume = "122",
pages = "3331--3334",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "19",

}

TY - JOUR

T1 - Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia

AU - Vainstein, Vladimir

AU - Eide, Christopher A.

AU - O'Hare, Thomas

AU - Shukron, Ofir

AU - Druker, Brian

PY - 2013/11/7

Y1 - 2013/11/7

N2 - BCR-ABL mutations result in clinical resistance to ABL tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Although in vitro 50% inhibitory concentration (IC50) values for specific mutations have been suggested to guide TKI choice in the clinic, the quantitative relationship between IC50and clinical response has never been demonstrated. We used Hill's equation for in vitro response of Ba/F3 cells transduced with various BCR-ABL mutants to determine IC50 and the slope of the dose-response curve. We found that slope variability between mutants tracked with in vitro TKI resistance, provides particular additional interpretive value in cases where in vitro IC50and clinical response are disparate. Moreover, unlike IC50alone, higher inhibitory potential at peak concentration (IPP), which integrates IC50, slope, and peak concentration (Cmax), correlated with improved complete cytogenetic response (CCyR) rates in CML patients treated with dasatinib. Our findings suggest a metric integrating in vitro and clinical data may provide an improved tool for BCR-ABL mutation-guided TKI selection.

AB - BCR-ABL mutations result in clinical resistance to ABL tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Although in vitro 50% inhibitory concentration (IC50) values for specific mutations have been suggested to guide TKI choice in the clinic, the quantitative relationship between IC50and clinical response has never been demonstrated. We used Hill's equation for in vitro response of Ba/F3 cells transduced with various BCR-ABL mutants to determine IC50 and the slope of the dose-response curve. We found that slope variability between mutants tracked with in vitro TKI resistance, provides particular additional interpretive value in cases where in vitro IC50and clinical response are disparate. Moreover, unlike IC50alone, higher inhibitory potential at peak concentration (IPP), which integrates IC50, slope, and peak concentration (Cmax), correlated with improved complete cytogenetic response (CCyR) rates in CML patients treated with dasatinib. Our findings suggest a metric integrating in vitro and clinical data may provide an improved tool for BCR-ABL mutation-guided TKI selection.

UR - http://www.scopus.com/inward/record.url?scp=84888211779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888211779&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-08-452409

DO - 10.1182/blood-2012-08-452409

M3 - Article

VL - 122

SP - 3331

EP - 3334

JO - Blood

JF - Blood

SN - 0006-4971

IS - 19

ER -